Funyu T, Nigawara K, Ohno K, Hamada W, Yagihashi Y
Clin Ther. 1981;3(6):456-66.
A benzothiazepine derivative, CRD-401, was administered orally in a dosage of 60 to 120 mg/day to 14 patients with various renal diseases. The systolic pressure was lowered slightly in some cases after administration of CRD-401. Urine volume and urinary excretion of electrolytes were increased by the drug in most patients except those with severe renal dysfunction. The plasma renin activity was increased to about twice the premedication value in most patients. Although the mechanism of increasing action of CRD-401 on plasma renin activity was assumed to be related to the reabsorption capacity of renal tubules for electrolytes, some questions still remain unanswered. The mechanism of this drug action, therefore, could not be elucidated completely in this study.
一种苯并硫氮䓬衍生物CRD - 401,以每日60至120毫克的剂量口服给予14名患有各种肾脏疾病的患者。在给予CRD - 401后,部分患者的收缩压略有降低。除了严重肾功能不全的患者外,大多数患者用药后尿量和电解质尿排泄量增加。大多数患者的血浆肾素活性增加至用药前值的两倍左右。尽管推测CRD - 401对血浆肾素活性的增强作用机制与肾小管对电解质的重吸收能力有关,但仍有一些问题未得到解答。因此,本研究未能完全阐明该药物的作用机制。